Suppr超能文献

肠-脑互动障碍相关的回避/限制型摄食障碍的短程认知行为治疗的开发:初步可行性、可接受性和临床结局。

Development of a brief cognitive-behavioral treatment for avoidant/restrictive food intake disorder in the context of disorders of gut-brain interaction: Initial feasibility, acceptability, and clinical outcomes.

机构信息

Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA.

Center for Neurointestinal Health, Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA.

出版信息

Int J Eat Disord. 2023 Mar;56(3):616-627. doi: 10.1002/eat.23874. Epub 2022 Dec 22.

Abstract

BACKGROUND

Avoidant/restrictive food intake disorder (ARFID) symptoms are common (up to 40%) among adults with disorders of gut-brain interaction (DGBI), but treatments for this population (DGBI + ARFID) have yet to be evaluated. We aimed to identify initial feasibility, acceptability, and clinical effects of an exposure-based cognitive-behavioral treatment (CBT) for adults with DGBI + ARFID.

METHODS

Patients (N = 14) received CBT as part of routine care in an outpatient gastroenterology clinic. A two-part investigation of the CBT included a retrospective evaluation of patients who were offered a flexible (8-10) session length and an observational prospective study of patients who were offered eight sessions. Feasibility benchmarks were ≥75% completion of sessions, quantitative measures (for treatment completers), and qualitative interviews. Acceptability was assessed with a benchmark of ≥70% patients reporting a posttreatment satisfaction scores ≥3 on 1-4 scale and with posttreatment qualitative interviews. Mixed model analysis explored signals of improvement in clinical outcomes.

RESULTS

All feasibility and acceptability benchmarks were achieved (and qualitative feedback revealed high satisfaction with the treatment and outcomes). There were improvements in clinical outcomes across treatment (all p's < .0001) with large effects for ARFID fear (-52%; Hedge's g = 1.5; 95% CI = 0.6, 2.5) and gastrointestinal-specific anxiety (-42%; Hedge's g = 1.0; 95% CI = 0.5, 16). Among those who needed to gain weight (n = 10), 94%-103% of expected weight gain goals were achieved.

DISCUSSION

Initial development and testing of a brief 8-session CBT protocol for DGBI + ARFID showed high feasibility, acceptability, and promising clinical improvements. Findings will inform an NIH Stage 1B randomized control trial.

PUBLIC SIGNIFICANCE

While cognitive-behavioral treatments (CBTs) for ARFID have been created in outpatient feeding and eating disorder clinics, they have yet to be developed and refined for other clinic settings or populations. In line with the recommendations for behavioral treatment development, we conducted a two-part investigation of an exposure-based CBT for a patient population with high rates of ARFID-adults with disorders of gut-brain interaction (also known as functional gastrointestinal disorders). We found patients had high satisfaction with treatment and there were promising improvements for both gastrointestinal and ARFID outcomes. The refined treatment includes eight sessions delivered by a behavioral health care provider and the findings reported in this article will be studied next in an NIH Stage 1B randomized controlled trial.

摘要

背景

在患有肠-脑互动障碍(DGBI)的成年人中,回避/限制型食物摄入障碍(ARFID)的症状很常见(高达 40%),但针对这一人群(DGBI + ARFID)的治疗方法尚未得到评估。我们旨在确定基于暴露的认知行为治疗(CBT)对患有 DGBI + ARFID 的成年人的初步可行性、可接受性和临床效果。

方法

患者(N=14)在门诊胃肠病诊所接受 CBT 作为常规护理的一部分。对 CBT 的两部分调查包括对接受灵活(8-10)次疗程的患者进行回顾性评估和对接受 8 次疗程的患者进行观察性前瞻性研究。可行性基准是完成疗程的比例≥75%、定量测量(针对治疗完成者)和定性访谈。可接受性通过以下基准来评估:≥70%的患者报告治疗后满意度评分≥1-4 分中的 3 分,以及治疗后定性访谈。混合模型分析探讨了临床结果改善的信号。

结果

所有可行性和可接受性基准均达到(定性反馈显示对治疗和结果非常满意)。在治疗过程中,临床结果均有所改善(所有 p 值均<.0001),对 ARFID 恐惧(-52%;Hedge's g=1.5;95%CI=0.6, 2.5)和胃肠道特异性焦虑(-42%;Hedge's g=1.0;95%CI=0.5, 16)的影响较大。在需要增重的患者中(n=10),达到预期增重目标的 94%-103%。

讨论

DGBI + ARFID 的简短 8 次 CBT 方案的初步开发和测试显示出较高的可行性、可接受性和有希望的临床改善。研究结果将为 NIH 阶段 1B 随机对照试验提供信息。

公众意义

虽然 ARFID 的认知行为治疗(CBT)已在门诊喂养和进食障碍诊所中创建,但尚未针对其他诊所环境或人群进行开发和完善。根据行为治疗开发的建议,我们对基于暴露的 CBT 进行了两部分调查,该 CBT 针对的是 ARFID 发病率高的患者人群——患有肠-脑互动障碍(也称为功能性胃肠道障碍)的成年人。我们发现患者对治疗非常满意,胃肠道和 ARFID 结果均有明显改善。经过改良的治疗包括由行为健康护理提供者提供的 8 次疗程,本研究报告的结果将在接下来的 NIH 阶段 1B 随机对照试验中进行研究。

相似文献

引用本文的文献

3
Avoidant/Restrictive Food Intake Disorder: Review and Recent Advances.回避/限制性摄食障碍:综述与最新进展
Focus (Am Psychiatr Publ). 2024 Jul;22(3):288-300. doi: 10.1176/appi.focus.20240008. Epub 2024 Jun 28.
4
Recent Advances in Cognitive-Behavioural Therapy for Eating Disorders (CBT-ED).进食障碍认知行为疗法的最新进展(CBT-ED)。
Curr Psychiatry Rep. 2024 Jul;26(7):351-358. doi: 10.1007/s11920-024-01509-0. Epub 2024 May 8.

本文引用的文献

3
Future of Brain-Gut Behavior Therapies: Mediators and Moderators.脑肠行为治疗的未来:中介和调节因素。
Gastroenterol Clin North Am. 2022 Dec;51(4):723-739. doi: 10.1016/j.gtc.2022.06.011. Epub 2022 Oct 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验